Retinal Vasculitis Secondary to Durvalumab

Ocular manifestations are very rarely reported as side effects to checkpoint inhibitors. We present a case of a 64-year-old Caucasian man in treatment with durvalumab for non-small-cell lung carcinoma who presented a retinal vasculitis with macular edema. After three boluses of methylprednisolone, t...

Full description

Bibliographic Details
Main Authors:	Antonio R. Andrade, Aina Moll-Udina, Ruth Martin, Esther Cilveti, Olaia Subirà, Laura Disfetano, Jose García-Arumí
Format:	Article
Language:	English
Published:	Karger Publishers 2020-05-01
Series:	Case Reports in Ophthalmology
Subjects:	vasculitis retina checkpoint inhibitors cancer therapy durvalumab
Online Access:	https://www.karger.com/Article/FullText/507609

id	doaj-495b06e704a14062a242770540e6b02d
record_format	Article
spelling	doaj-495b06e704a14062a242770540e6b02d2020-11-25T03:07:25ZengKarger PublishersCase Reports in Ophthalmology1663-26992020-05-0111216116610.1159/000507609507609Retinal Vasculitis Secondary to DurvalumabAntonio R. AndradeAina Moll-UdinaRuth MartinEsther CilvetiOlaia SubiràLaura DisfetanoJose García-ArumíOcular manifestations are very rarely reported as side effects to checkpoint inhibitors. We present a case of a 64-year-old Caucasian man in treatment with durvalumab for non-small-cell lung carcinoma who presented a retinal vasculitis with macular edema. After three boluses of methylprednisolone, the retinal vasculitis resolved and macular edema improved during follow-up. There was no need for durvalumab to be withdrawn.https://www.karger.com/Article/FullText/507609vasculitisretinacheckpoint inhibitorscancer therapydurvalumab
collection	DOAJ
language	English
format	Article
sources	DOAJ
author	Antonio R. Andrade Aina Moll-Udina Ruth Martin Esther Cilveti Olaia Subirà Laura Disfetano Jose García-Arumí
spellingShingle	Antonio R. Andrade Aina Moll-Udina Ruth Martin Esther Cilveti Olaia Subirà Laura Disfetano Jose García-Arumí Retinal Vasculitis Secondary to Durvalumab Case Reports in Ophthalmology vasculitis retina checkpoint inhibitors cancer therapy durvalumab
author_facet	Antonio R. Andrade Aina Moll-Udina Ruth Martin Esther Cilveti Olaia Subirà Laura Disfetano Jose García-Arumí
author_sort	Antonio R. Andrade
title	Retinal Vasculitis Secondary to Durvalumab
title_short	Retinal Vasculitis Secondary to Durvalumab
title_full	Retinal Vasculitis Secondary to Durvalumab
title_fullStr	Retinal Vasculitis Secondary to Durvalumab
title_full_unstemmed	Retinal Vasculitis Secondary to Durvalumab
title_sort	retinal vasculitis secondary to durvalumab
publisher	Karger Publishers
series	Case Reports in Ophthalmology
issn	1663-2699
publishDate	2020-05-01
description	Ocular manifestations are very rarely reported as side effects to checkpoint inhibitors. We present a case of a 64-year-old Caucasian man in treatment with durvalumab for non-small-cell lung carcinoma who presented a retinal vasculitis with macular edema. After three boluses of methylprednisolone, the retinal vasculitis resolved and macular edema improved during follow-up. There was no need for durvalumab to be withdrawn.
topic	vasculitis retina checkpoint inhibitors cancer therapy durvalumab
url	https://www.karger.com/Article/FullText/507609
work_keys_str_mv	AT antoniorandrade retinalvasculitissecondarytodurvalumab AT ainamolludina retinalvasculitissecondarytodurvalumab AT ruthmartin retinalvasculitissecondarytodurvalumab AT esthercilveti retinalvasculitissecondarytodurvalumab AT olaiasubira retinalvasculitissecondarytodurvalumab AT lauradisfetano retinalvasculitissecondarytodurvalumab AT josegarciaarumi retinalvasculitissecondarytodurvalumab
_version_	1724670600982560768

Retinal Vasculitis Secondary to Durvalumab

Similar Items